T1	Age 24 35	54-year-old
T2	Gender 36 42	female
T3	Activity 47 55	admitted
E1	Activity:T3 
T4	Disease_disorder 107 109	HF
E2	Disease_disorder:T4 
T5	Disease_disorder 168 170	MI
E3	Disease_disorder:T5 
T6	Qualitative_concept 162 167	acute
R1	MODIFY Arg1:T6 Arg2:E3	
T7	Diagnostic_procedure 184 204	coronary angiography
E4	Diagnostic_procedure:T7 
T8	Activity 80 103	diagnosis and treatment
E5	Activity:T8 
T9	Sign_symptom 206 250	total occlusion of the right coronary artery
E6	Sign_symptom:T9 
T10	Disease_disorder 256 278	collateral circulation
E7	Disease_disorder:T10 
T11	Anatomical_structure 288 320	left descending coronary artery)
T12	Therapeutic_procedure 356 378	coronary intervention.
E8	Therapeutic_procedure:T12 
R2	MODIFY Arg1:E6 Arg2:E3	
T13	Anatomical_structure 229 250	right coronary artery
T14	Subject 326 333	patient
A1	POLARITY E8 NEG
T15	Disease_disorder 408 410	MI
E9	Disease_disorder:T15 
T16	Activity 415 424	diagnosed
E10	Activity:T16 
T17	Subject 430 437	patient
T18	Activity 442 452	classified
E11	Activity:T18 
T19	Sign_symptom 456 531	Class III according to the New York Heart Association (NYHA) classification
E12	Sign_symptom:T19 
T20	Activity 533 552	Further examination
E13	Activity:T20 
T22	Sign_symptom 649 668	cardiac enlargement
E14	Sign_symptom:T22 
T21	Sign_symptom 565 647	elevated level of Nterminal-pro-brain natriuretic peptide (NT-proBNP, 10581 pg/mL)
E15	Sign_symptom:T21 
T23	Quantitative_concept 565 579	elevated level
T24	Lab_value 624 633	NT-proBNP
T25	Lab_value 583 622	Nterminal-pro-brain natriuretic peptide
T26	Quantitative_concept 636 646	0581 pg/mL
T27	Sign_symptom 678 742	ncreased left ventricular end-diastolic diameter (LVEDD, 81 mm),
E16	Sign_symptom:T27 
T28	Lab_value 728 733	LVEDD
T29	Quantitative_concept 735 740	81 mm
T30	Sign_symptom 743 792	low left ventricular ejection fraction (LVEF, 25%
E17	Sign_symptom:T30 
T31	Lab_value 783 788	LVEF,
T32	Quantitative_concept 789 793	25%)
T33	Sign_symptom 799 807	akinesis
E18	Sign_symptom:T33 
T34	Anatomical_structure 815 861	inferior, inferoseptal and inferolateral walls
T35	Sign_symptom 867 892	severe global hypokinesis
E19	Sign_symptom:T35 
T36	Quantitative_concept 867 873	severe
T37	Anatomical_structure 902 929	walls of the left ventricle
T38	Subject 947 954	patient
T39	Activity 964 971	treated
E20	Activity:T39 
T40	Disease_disorder 976 979	CAD
E21	Disease_disorder:T40 
T41	Disease_disorder 996 1017	arterial hypertension
E22	Disease_disorder:T41 
T42	Disease_disorder 1019 1040	hypercholesterolaemia
E23	Disease_disorder:T42 
T43	Disease_disorder 1042 1064	ventricular arrhythmia
E24	Disease_disorder:T43 
T44	Medication 1066 1076	carvedilol
E25	Medication:T44 
T45	Age 1078 1086	ramipril
T46	Medication 1088 1102	spironolactone
E26	Medication:T46 
T47	Age 1104 1114	furosemide
T48	Medication 1116 1128	atorvastatin
E27	Medication:T48 
T49	Medication 1130 1143	trimetazidine
E28	Medication:T49 
T50	Medication 1145 1152	aspirin
E29	Medication:T50 
T51	Time 1155 1171	Two months later
E30	Time:T51 
T52	Activity 1184 1193	admission
E31	Activity:T52 
T53	Sign_symptom 1240 1253	NYHA class II
E32	Sign_symptom:T53 
T54	Lab 1255 1275	NT-proBNP 1869 pg/mL
E33	Lab:T54 
T55	Lab 1277 1288	LVEDD 73 mm
E34	Lab:T55 
T56	Lab 1290 1298	LVEF 35%
E35	Lab:T56 
T57	Lab 1305 1344	nferior and inferolateral wall akinesis
E36	Lab:T57 
T58	Lab 1349 1369	moderate hypokinesis
E37	Lab:T58 
T59	Quantitative_concept 1265 1275	1869 pg/mL
T60	Quantitative_concept 1283 1289	73 mm,
T61	Quantitative_concept 1295 1298	35%
T62	Lab_value 1304 1335	inferior and inferolateral wall
T63	Diagnostic_procedure 1387 1426	Cardiovascular magnetic resonance (CMR)
E38	Diagnostic_procedure:T63 
T64	Sign_symptom 1462 1495	late gadolinium enhancement (LGE)
E39	Sign_symptom:T64 
T65	Anatomical_structure 1503 1526	inferoseptal (mid-wall)
T66	Anatomical_structure 1538 1553	sub-endocardial
T67	Anatomical_structure 1559 1593	inferolateral (transmural) walls .
